Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma
Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma
Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
3. Somatosensory function and neuropathic pain grading<br />
3.2.2. Grading of neuropathic pain<br />
Patient’s pain was graded into ‘definite neuropathic’ (n=26), ‘probable neuropathic’<br />
(n=39), ‘possible neuropathic’ (n=9) and ‘unlikely neuropathic’ (n=34) according to the<br />
classification by Treede and colleagues (Treede et al 2008). Thus, of the 108 neuropathic<br />
pain patients investigated, 60% were graded as having ‘definite’ and ‘probable’<br />
neuropathic pain. Out of this group 40% were accounted as ‘definite’ neuropathic. For<br />
patients graded as ‘probable’ neuropathic pain, 67% (n=26) a diagnostic test was not<br />
performed and 33% (n=13) had a negative outcome of the diagnostic test. Interestingly,<br />
in one patient with ‘probable’ neuropathic pain grading the diagnostic test was positive<br />
but the confirmatory test was negative (Table 3-1).<br />
All nine patients graded as ‘possible’ neuropathic pain did not have their sensory signs<br />
in a neuroanatomical confined territory. For this patient group more confirmatory and<br />
diagnostic work would be necessary to advance this group to ‘probable’ neuropathic<br />
pain. 31% of the clinically diagnosed neuropathic pain patients were graded as ‘unlikely’<br />
neuropathic pain. This was due to the fact that there was a lack of history of patient’s<br />
lesion or disease and their pain complaints were not in a plausible neuroanatomical<br />
distribution (Table 3-1).<br />
3.3. Type of sensory abnormalities in relation to neuropathic pain grading<br />
3.3.1. <strong>Sensory</strong> loss and/or gain of function<br />
For the 108 patients investigated in this study, 1404 <strong>QST</strong> data measurements were<br />
obtained. In patients with neuropathic pain, sensory abnormalities were observed in all<br />
<strong>QST</strong> parameters. In our patient cohort, 94% had at least one <strong>QST</strong> abnormality. From<br />
these patients 51% had a mixture of sensory gain and loss, 26% had only sensory gain<br />
(hyperalgesia) and 16% had only sensory loss (hypesthesia) (Fig. 3-1).<br />
The profiles of sensory signs in ‘definite’ and ‘probable’ neuropathic pain were not<br />
significantly different, but different from the ‘unlikely’ grade. This latter difference<br />
was due to an increase of a mixture of sensory gain and loss and a decrease in frequency<br />
of sensory loss only for the ‘unlikely’ grade compared to the ‘definite’ and ‘probable’<br />
neuropathic pain grade (all p